A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.


Objective To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups. The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.

Full Title of Study: “A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single

Detailed Description

All products were used according to the manufacturer's instructions. KP24 and Banlice were applied twice separated by a one week interval. MOOV Head Lice Treatment was applied on Day 0, Day 7 and Day 14. The cure rate (absence of live lice) one day after the first administration for all products was a secondary outcome measure. The cure rate at 7 days after the final administration (Day 14 for Banlice or KP24 and at Day 21 for MOOV Head Lice Treatment) was the primary outcome measure. Siblings were treated if these were found to be infected as an enrolment criteria.


  • Drug: 1) MOOV Head Lice Treatment (Ego Pharmaceutical).
  • Drug: Banlice Mousse Aerosol (Pfizer, Australia)
  • Drug: 3) KP24 Medicated Foam (Nelson Laboratories)

Clinical Trial Outcome Measures

Primary Measures

  • Absence of live head lice one week after the last treatment for each product (ie at Day 14 for KP24 and Banlice and at Day 21 for MOOV Head Lice Treatment)

Secondary Measures

  • Absence of live head lice one day after the first treatment of each product

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female primary school children. – Presence of live head lice (adults or nymphs) on the hair or scalp. The presence of live lice will be determined from a visual inspection of the hair and scalp and Dry-combing of the hair. Combing will stop immediately once live lice are observed. The presence of lice eggs alone is not a sufficient condition for inclusion in the trial. – Be available for the duration of the trial. – Parent / Guardian is willing not to use other head lice products or methods (e.g. combs) to treat their child's head lice for 21 days after the first treatment. – Parent / Guardian has given written informed consent to their child's participation in the trial. Exclusion Criteria:

  • History of allergies or adverse reactions to head lice products or the components of the specific products being tested. – Treatment with any head lice product in the month prior to Day 0. – Presence of scalp disease(s). – If a subject has a sibling in Grade 1-7 this sibling must also be enrolled in the study and treated on Day 0 otherwise the subject must be considered ineligible for enrolment. – Subjects must have one fixed place of residence

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: 12 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Uniquest Pty Ltd
  • Collaborator
    • Ego Pharmaceuticals
  • Overall Official(s)
    • Stephen Barker, PhD, Principal Investigator, The University of Queensland

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.